Arrowhead Research reported $-1.36 in EPS Earnings Per Share for its fiscal quarter ending in June of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q4 Sep/2026 -1.12 -0.11 Nov/12
FY2026Q3 Jun/2026 -1.36 -1.20 -1.26 Aug/04
FY2026Q2 Mar/2026 -0.93 -1.04 2.75 May/07
FY2026Q1 Dec/2025 0.22 0.04 -1.39 Feb/05
FY2025Q4 Sep/2025 -0.11 -0.23 -1.36 Nov/25




Eps Change Date
Agios Pharmaceuticals USD -1.09 0.6 Sep/2026
Alnylam Pharmaceuticals USD 16.26 14.42 Sep/2026
Anika Therapeutics USD 0.13 0.35 Dec/2025
Arrowhead Research USD -1.36 0.43 Jun/2026
Heron Therapeutics USD -0.02 0.02 Dec/2025
Incyte USD -3.6 6.69 Sep/2026
Ionis Pharmaceuticals USD 0.66 1.35 Sep/2026
Ligand Pharmaceuticals USD 2.67 0.3 Sep/2026
Merck USD 2.49 2.62 Sep/2026
Moderna USD 0.38 2.35 Sep/2026
Nektar Therapeutics USD -1.78 0.43 Mar/2026
Novartis USD 2.46 0.05 Sep/2026
Sarepta Therapeutics USD 0.13 0.51 Sep/2026
TG Therapeutics USD 0.35 0.3 Sep/2026
Ultragenyx Pharmaceutical USD -1.16 0.26 Sep/2026
Vertex Pharmaceuticals USD 4.76 0.03 Sep/2026
Xencor USD 0.5 0.79 Sep/2026